

Beovu® (brolucizumab-dblI)

When requesting Beovu® (brolucizumab-dblI), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or the approved off-label compendial use and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indications

Beovu is indicated for treatment of the following:

- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)

Approved Off-Label Compendial Uses

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, retinopathy of prematurity, angioid streaks, iris neovascularization, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy, presumed ocular histoplasmosis)

Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- Beovu is administered by or under the supervision of an ophthalmologist.

Approval duration: 12 months

Dosing Recommendation

Beovu is administered by intravitreal injection as follows:

- For neovascular age-related macular degeneration and other neovascular diseases of the eye: the recommended dose of Beovu is 6 mg monthly (approximately every 25-31 days) for the first three doses, followed by 6 mg every 8-12 weeks.
- For diabetic macular edema: the recommended dose of Beovu is 6 mg once every 6 weeks (approximately every 39 to 45 days) for the first five doses, followed by 6 mg every 8-12 weeks.

References

1. Beovu® [prescribing information]. Hanover, NJ: Novartis Pharmaceuticals; July 2024.
2. Hang A, Feldman S, Amin AP, et al. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. *Pharmaceuticals*. 2023;16:1140. Doi.org/10.3390/ph16081140.